SCH-50971

Last updated

SCH-50971
SCH-50971.svg
Clinical data
Other namesSch-50971
Routes of
administration 		Oral [1]
Drug class Histamine H3 receptor agonist
ATC code
  • None
Identifiers
  • 5-[(3R,4R)-4-methylpyrrolidin-3-yl]-1H-imidazole
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
Formula C8H13N3
Molar mass 151.213 g·mol−1
3D model (JSmol)
  • C[C@H]1CNC[C@@H]1C2=CN=CN2
  • InChI=1S/C8H13N3/c1-6-2-9-3-7(6)8-4-10-5-11-8/h4-7,9H,2-3H2,1H3,(H,10,11)/t6-,7-/m0/s1
  • Key:KTEPQLOOQDLKHF-BQBZGAKWSA-N

SCH-50971 is a histamine H3 receptor agonist which was under development for the treatment of anxiety disorders, gastrointestinal disorders, and migraine but was never marketed. [2] [3]

Contents

Pharmacology

The drug acts as a potent, selective, and high-affinity agonist of the histamine H3 receptor. [4] [5] It has negligible affinity for the histamine H1 receptor and other assessed receptors. [4] The drug is also not a histamine H2 receptor antagonist. [4] It has greatly improved selectivity compared to the earlier selective histamine H3 receptor agonist (R)-α-methylhistamine. [4] [5] The drug is orally active and shows anti-allergy effects, antimigraine effects, sedative and hypnotic effects, and hypolocomotion in animals. [6] [7] [1] In terms of chemical structure, it is a cyclized pyrrolidine derivative of histamine. [8] [4]

Development

SCH-50971 was under development by Schering-Plough. [2] It reached the discovery or preclinical research stage of development. [3] The development of the drug was discontinued by 2001. [2] SCH-50971 was first described in the scientific literature by 1994. [9] [10]

See also

References

  1. 1 2 McLeod RL, Aslanian R, del Prado M, Duffy R, Egan RW, Kreutner W, et al. (October 1998). "Sch 50971, an orally active histamine H3 receptor agonist, inhibits central neurogenic vascular inflammation and produces sedation in the guinea pig". The Journal of Pharmacology and Experimental Therapeutics. 287 (1): 43–50. doi:10.1016/S0022-3565(24)37761-4. PMID   9765320.
  2. 1 2 3 "SCH 50971". AdisInsight. 7 September 2001. Retrieved 6 October 2025.
  3. 1 2 "Delving into the Latest Updates on Sch-50971 with Synapse". Synapse. 13 September 2025. Retrieved 6 October 2025.
  4. 1 2 3 4 5 Hey JA, Aslanian R, Bolser DC, Chapman RW, Egan RW, Rizzo CA, et al. (September 1998). "Studies on the pharmacology of the novel histamine H3 receptor agonist Sch 50971". Arzneimittel-Forschung. 48 (9): 881–888. PMID   9793613.
  5. 1 2 Shih NY, Aslanian R, Lupo AT, Orlando S, Piwinski JJ, Green MJ, et al. (February 1998). "Trans-4-methyl-3-imidazoyl pyrrolidine as a potent, highly selective histamine H3 receptor agonist in vivo". Bioorganic & Medicinal Chemistry Letters. 8 (3): 243–248. doi:10.1016/s0960-894x(98)00020-1. PMID   9871662.
  6. ↑ Yokota E, Kuyama S, Ogawa M, Kamei C (August 2008). "Substance P is involved in the effect of histamine H3 receptor agonist, Sch 50971 on nasal allergic symptoms in mice". International Immunopharmacology. 8 (8): 1083–1088. doi:10.1016/j.intimp.2008.03.018. PMID   18550011.
  7. ↑ Yokota E, Kuyama S, Sugimoto Y, Ogawa M, Kamei C (October 2008). "Participation of histamine H3 receptors in experimental allergic rhinitis of mice". Journal of Pharmacological Sciences. 108 (2): 206–211. doi:10.1254/jphs.08164fp. PMID   18845911.
  8. ↑ "4-((3R,4R)-4-methylpyrrolidin-3-yl)-1H-imidazole". PubChem. Retrieved 6 October 2025.
  9. ↑ Leurs R, Vollinga RC, Timmerman H (1995). "The medicinal chemistry and therapeutic potentials of ligands of the histamine H3 receptor". Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des Recherches Pharmaceutiques. Vol. 45. pp. 107–165. doi:10.1007/978-3-0348-7164-8_4. ISBN   978-3-0348-7166-2. PMID   8545536.
  10. ↑ Sippl W, Stark H, Höltje HD (1995). "Computer-Assisted Analysis of Histamine H 2 − and H 3 -Receptor Agonists". Quantitative Structure-Activity Relationships. 14 (2): 121–125. doi:10.1002/qsar.19950140203. ISSN   0931-8771 . Retrieved 6 October 2025.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.